Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Aim(s): Evaluation of the efficacy and tolerability of monotherapy TMZ as 2nd and 3rd line treatment after platin-based chemotherapy in patients with PDEC.
Materials and methods: Patients with PDEC (small cell lung carcinomas excluded). WHO performance status 0-2. Adequate organ function tests. At least one previous platin-containing chemotherapy regimen. Informed consent. TMZ schedule: 200 mg/sqm orally days 1-5 every 28 days. Response evaluation at least every three courses.
Conference: 8th Annual ENETSConcerence (2011)
To read the full abstract, please log into your ENETS Member account.